Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Nomograms for colorectal cancer: A systematic review.

Kawai K, Sunami E, Yamaguchi H, Ishihara S, Kazama S, Nozawa H, Hata K, Kiyomatsu T, Tanaka J, Tanaka T, Nishikawa T, Kitayama J, Watanabe T.

World J Gastroenterol. 2015 Nov 7;21(41):11877-86. doi: 10.3748/wjg.v21.i41.11877.

2.

Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?

Kim SJ, Jeong TY, Yoo DS, Park J, Cho S, Kang SH, Lee SH, Jeon SH, Lee TY, Park SY.

Yonsei Med J. 2015 Nov;56(6):1492-6. doi: 10.3349/ymj.2015.56.6.1492.

3.

Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.

Rubio-Briones J, Borque A, Esteban LM, Casanova J, Fernandez-Serra A, Rubio L, Casanova-Salas I, Sanz G, Domínguez-Escrig J, Collado A, Gómez-Ferrer A, Iborra I, Ramírez-Backhaus M, Martínez F, Calatrava A, Lopez-Guerrero JA.

BMC Cancer. 2015 Sep 11;15:633. doi: 10.1186/s12885-015-1623-0.

4.

Systematic review of clinical features of suspected prostate cancer in primary care.

Young SM, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A.

Can Fam Physician. 2015 Jan;61(1):e26-35. Review.

5.

Guideline for referral of patients with suspected prostate cancer by family physicians and other primary care providers.

Young SM, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A; Prostate Cancer Referral Working Group.

Can Fam Physician. 2015 Jan;61(1):33-9.

6.

Prostate cancer screening: and yet it moves!

Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F.

Asian J Androl. 2015 May-Jun;17(3):437-8. doi: 10.4103/1008-682X.143310.

7.

Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.

Gotto GT, Yu C, Bernstein M, Eastham JA, Kattan MW.

Front Oncol. 2014 Oct 27;4:296. doi: 10.3389/fonc.2014.00296. eCollection 2014.

8.

Community differentiation of the cutaneous microbiota in psoriasis.

Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé BA, Blaser MJ.

Microbiome. 2013 Dec 23;1(1):31. doi: 10.1186/2049-2618-1-31.

9.

Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Cary KC, Cooperberg MR.

Ther Adv Urol. 2013 Dec;5(6):318-29. doi: 10.1177/1756287213495915. Review.

10.

Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy.

Jeong IG, Lim JH, Hwang SS, Kim SC, You D, Hong JH, Ahn H, Kim CS.

Prostate Int. 2013;1(2):69-75. doi: 10.12954/PI.12008. Epub 2013 Jun 30.

11.

The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting.

Liang Y, Ankerst DP, Feng Z, Fu R, Stanford JL, Thompson IM.

Urol Oncol. 2013 Nov;31(8):1464-9. doi: 10.1016/j.urolonc.2012.03.012. Epub 2012 May 1.

12.

Synthesis of bombesin-functionalized iron oxide nanoparticles and their specific uptake in prostate cancer cells.

Martin AL, Hickey JL, Ablack AL, Lewis JD, Luyt LG, Gillies ER.

J Nanopart Res. 2009 Jun 23;12(5):1599-1608.

13.

Prostate cancer risk prediction in a urology clinic in Mexico.

Liang Y, Messer JC, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR.

Urol Oncol. 2013 Oct;31(7):1085-92. doi: 10.1016/j.urolonc.2011.12.023. Epub 2012 Feb 3.

14.

Risk-based prostate cancer screening.

Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ.

Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24. Review.

15.

Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Ahmed HU, Akin O, Coleman JA, Crane S, Emberton M, Goldenberg L, Hricak H, Kattan MW, Kurhanewicz J, Moore CM, Parker C, Polascik TJ, Scardino P, van As N, Villers A; Transatlantic Consensus Group on Active Surveillance and Focal Therapy for Prostate Cancer (appendix).

BJU Int. 2012 Jun;109(11):1636-47. doi: 10.1111/j.1464-410X.2011.10633.x. Epub 2011 Nov 11.

16.

An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis.

Kiciński M, Vangronsveld J, Nawrot TS.

PLoS One. 2011;6(10):e27130. doi: 10.1371/journal.pone.0027130. Epub 2011 Oct 31.

17.

Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.

Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG.

Cancer. 2012 May 15;118(10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17.

18.

Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network.

Kim SY, Moon SK, Jung DC, Hwang SI, Sung CK, Cho JY, Kim SH, Lee J, Lee HJ.

Korean J Radiol. 2011 Sep-Oct;12(5):588-94. doi: 10.3348/kjr.2011.12.5.588. Epub 2011 Aug 24.

19.

Tumor markers in prostate cancer I: blood-based markers.

Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.

Acta Oncol. 2011 Jun;50 Suppl 1:61-75. doi: 10.3109/0284186X.2010.542174. Review.

20.

Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing.

Park JY, Yoon S, Park MS, Cho DY, Park HS, Moon du G, Yoon DK.

J Korean Med Sci. 2011 Jan;26(1):85-91. doi: 10.3346/jkms.2011.26.1.85. Epub 2010 Dec 22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk